GenMark Diagnostics (GNMK) Reports In-Line Q3 EPS

GenMark Diagnostics (NASDAQ: GNMK) reported Q3 EPS of ($0.29), in-line with the analyst estimate of ($0.29). Revenue for the quarter came in at $1.3 million versus the consensus estimate of $1.28 million.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• Rein Therapeutics Inc. (RNTX) Tops Q2 EPS by 39c
• Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c